Melanoma

E301: AP-2α Regulates Uveal Melanoma Proliferation In Vitro

E302: International Survey on Evidence for Index Lymph Node (ILN) Surgery Following Neoadjuvant Systemic Therapy (NST) for Stage III Melanoma

E303: Trends in Complete Lymph Node Dissection for Melanoma Patients Post-MSLT2 Trial: Insights from the Vizient Database

E304: Real World Experience with Regional Lymphadenectomy for Clinical Stage III Malignant Melanoma in the Setting of Immunotherapy

E305: The Utility of Sentinel Lymph Node Biopsy in Elderly Patients with Melanoma

E307: Defining the Sentinel Lymph Node in Melanoma: Is the Hottest Node Always the Node with Metastases

E308: Sentinel Lymph Node Biopsy for Desmoplastic Melanoma: More Frequently Performed and Less Likely to be Beneficial

E309: Utility of 31-gene expression profile test in identifying patients with T1 cutaneous melanoma at high risk of SLN positivity and recurrence

E310: Impact of FDA Approvals on the Use of Adjuvant Systemic Therapy for Node-Positive Melanoma

E311: Genetic Screening of Malignant Melanoma Patients at a Tertiary Care Center

E312: Macrophage function over phenotype determines sensitization to immunotherapy

E313: Clinical Implications of Collision Tumors on Long-Term Outcomes in Merkel Cell Carcinoma

E314: Telomerase reverse transcriptase (TERT) promoter mutations are associated with higher tumor mutational burden and UV mutational signature in melanoma

E315: Surgical Management of Metastatic Melanoma to the Gastrointestinal Tract in the Age of Immunotherapy

E316: The young nodal basin: Update on regional metastasis and clinical outcomes in young cutaneous melanoma patients

E317: Risk of Postoperative Venous Thromboembolism in Patients with Lower Extremity Melanoma

E319: The impact of a Regional Communities of Practice to improve quality of melanoma care: setting guidelines for preoperative diagnostic imaging in early stage melanoma

E320: Isolated Limb Infusion as First, Second, or Third-Line Therapy for Melanoma with In-Transit Metastasis

E321: An evaluation of sentinel lymph node biopsy guideline adherence in melanoma patients

E322: Transcription Factor E3 (TFE3) Regulates the Invasive Phenotype in MITF-low Melanoma

E323: A Single Institution Experience Using Ultrasound-Guided Intralesional Immunotherapy in Recurrent Melanoma

E324: A Cost-Effectiveness Analysis of Tumor Infiltrating Lymphocytes (TIL) versus Pembrolizumab for Metastatic Melanoma

E325: Overall Survival Comparing Neoadjuvant versus Adjuvant Alone Immunotherapy in Clinical Stage III Melanoma

E326: Factors Associated with Recurrence Risk and Survival in Patients with Acral Melanoma

E327: Management of Anorectal Melanoma in the Era of Modern Systemic Therapies

E328: Sentinel Lymph Node Biopsy in Thin Melanoma: Is It Necessary?

E329: Long term outcomes and pattern of recurrence in patients with thin melanoma and a negative sentinel lymph node biopsy- a single center experience

E330: Contemporary Radiographic Staging Practices among Patients with Pathologic Stage III Melanoma Undergoing Adjuvant Immune Therapy

E331: Are positive biopsy margins in melanoma significant? – A cohort study of micro- versus macroscopic margin status and their impact on residual disease and survival

E332: Sequencing of Discordant Lesions in a Merkel Cell Carcinoma Patient Reveals SH2B3 Mutation as a Potential Resistance Mechanism to Oncolytic Virus Therapy

E334: Surgical management of plantar melanoma: a retrospective review analyzing frequency of upstaging at a single NCI-designated cancer institution.

E335: Timing of definitive surgical treatment of primary cutaneous melanoma: impact on survival

E336: Rising Waves of Neoadjuvant Immunotherapies: Trends in High-Risk and Advanced Melanoma Treatment

P38: Salvage Metastasectomy after Adoptive Cell Transfer for Melanoma: Long-Term Updates

P39: Hyperthermic Isolated Limb Perfusion in the Era of Effective Systemic Immunotherapy

P40: Frequency and Predictors of Metastatic Disease in Sentinel Node Positive Malignant Melanoma

P41: Whole Transcriptome Profiling of Patients with In Transit Melanoma

P42: Utilization of the Melanoma Institute of Australia's Sentinel Lymph Node Metastasis Risk Calculator Reduces Sentinel Lymph Node Biopsy Utilization in T1 Cutaneous Melanoma

P43: Innovation in Collaborating and Funding an International Cancer Clinical Trial

P44: Social Determinants of Health Predict Lower Receipt of Systemic Treatment and Worse Survival in Patients with Metastatic Melanoma

P45: Head & neck primary cutaneous melanoma patients stratified by CP-GEP (Merlin Assay): risk of nodal metastasis and long-term survival outcome